Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | S100A4 | P26447 | 3/20 | 0.45 |
| ▸ | PTPRC | P08575 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | FGB | P02675 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | PLEC | Q15149 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2333693 | 0.90 | MAPT (0.50) | MAPTKMT2ARECQLMCL1RXFP1 | |
| SCHEMBL768880 | 0.90 | MAPT (0.53) | MAPTKMT2ARECQLMCL1RXFP1 | |
| SCHEMBL4573599 | 0.87 | MAPT (0.53) | MAPTKMT2ARECQLMCL1RXFP1 | |
| SCHEMBL16445689 | 0.83 | ALDH1A1 (0.47) | MAPTKMT2ARECQLMCL1RXFP1 | |
| SCHEMBL28041457 | 0.81 | MAOA (0.56) | KMT2ACYP2A6MAOAMAOBHSD17B10 | |
| SCHEMBL166701 | 0.80 | MAPT (0.56) | MAPTKMT2ARECQLMCL1RXFP1 | |
| SCHEMBL35211484 | 0.80 | MAPT (0.56) | MAPTKMT2ARECQLMCL1RXFP1 | |
| SCHEMBL30535903 | 0.75 | ALDH1A1 (0.74) | KMT2ARECQLTDP1ALDH1A1S100A4 | |
| SCHEMBL1287837 | 0.75 | ALDH1A1 (0.74) | KMT2ARECQLTDP1ALDH1A1S100A4 | |
| SCHEMBL2335721 | 0.75 | ALDH1A1 (0.49) | MAPTKMT2ARECQLMCL1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160368872-A1 | COMPOUNDS AND METHODS FOR TREATING CANCERS | PANACELA LABS, INC. | 2016-12-22 | — | — | US | disclosed |
| US-20160368872-A1 | COMPOUNDS AND METHODS FOR TREATING CANCERS | PANACELA LABS, INC. | 2016-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368872-A1 | COMPOUNDS AND METHODS FOR TREATING CANCERS | KLK3, AR, BRDT | MAPT 3369/4885KMT2A 1813/4885RECQL 4829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.